Browsing Clinical Studies by author "Melcher, Alan"
Now showing items 1-9 of 9
-
Antiviral antibody responses to systemic administration of an oncolytic RNA virus: the impact of standard concomitant anticancer chemotherapies.
Roulstone, V; Mansfield, D; Harris, RJ; Twigger, K; White, C; et al. (BMJ PUBLISHING GROUP, 2021-01-01)BACKGROUND: Oncolytic reovirus therapy for cancer induces a typical antiviral response to this RNA virus, including neutralizing antibodies. Concomitant treatment with cytotoxic chemotherapies has been hypothesized to ... -
CEA expression heterogeneity and plasticity confer resistance to the CEA-targeting bispecific immunotherapy antibody cibisatamab (CEA-TCB) in patient-derived colorectal cancer organoids.
Gonzalez-Exposito, R; Semiannikova, M; Griffiths, B; Khan, K; Barber, LJ; et al. (BMJ PUBLISHING GROUP, 2019-03-21)BACKGROUND: The T cell bispecific antibody cibisatamab (CEA-TCB) binds Carcino-Embryonic Antigen (CEA) on cancer cells and CD3 on T cells, which triggers T cell killing of cancer cell lines expressing moderate to high ... -
Comprehensive characterization of immune landscape of Indian and Western triple negative breast cancers.
Korlimarla, A; Ps, H; Prabhu, J; Ragulan, C; Patil, Y; et al. (ELSEVIER SCIENCE INC, 2022-11-01)PURPOSE: Triple-negative breast cancer (TNBC) is a heterogeneous disease with a significant challenge to effectively manage in the clinic worldwide. Immunotherapy may be beneficial to TNBC patients if responders can be ... -
Computational Image Analysis of T-Cell Infiltrates in Resectable Gastric Cancer: Association with Survival and Molecular Subtypes.
Challoner, BR; von Loga, K; Woolston, A; Griffiths, B; Sivamanoharan, N; et al. (OXFORD UNIV PRESS INC, 2021-01-04)BACKGROUND: Gastric and gastro-esophageal junction cancers (GCs) frequently recur after resection, but markers to predict recurrence risk are missing. T-cell infiltrates have been validated as prognostic markers in other ... -
Immune landscape, evolution, hypoxia-mediated viral mimicry pathways and therapeutic potential in molecular subtypes of pancreatic neuroendocrine tumours.
Young, K; Lawlor, RT; Ragulan, C; Patil, Y; Mafficini, A; et al. (BMJ PUBLISHING GROUP, 2020-09-03)OBJECTIVE: A comprehensive analysis of the immune landscape of pancreatic neuroendocrine tumours (PanNETs) was performed according to clinicopathological parameters and previously defined molecular subtypes to identify ... -
Intravenous delivery of oncolytic reovirus to brain tumor patients immunologically primes for subsequent checkpoint blockade.
Samson, A; Scott, KJ; Taggart, D; West, EJ; Wilson, E; et al. (AMER ASSOC ADVANCEMENT SCIENCE, 2018-01-03)Immune checkpoint inhibitors, including those targeting programmed cell death protein 1 (PD-1), are reshaping cancer therapeutic strategies. Evidence suggests, however, that tumor response and patient survival are determined ... -
Oncolytic Herpes Simplex Virus Inhibits Pediatric Brain Tumor Migration and Invasion.
Cockle, JV; Brüning-Richardson, A; Scott, KJ; Thompson, J; Kottke, T; et al. (CELL PRESS, 2017-06-16)Pediatric high-grade glioma (pHGG) and diffuse intrinsic pontine glioma (DIPG) are invasive tumors with poor survival. Oncolytic virotherapy, initially devised as a direct cytotoxic treatment, is now also known to act via ... -
Pembrolizumab in Combination with Radiotherapy for Metastatic Melanoma - Introducing the PERM Trial.
Yip, K; Melcher, A; Harrington, K; Illidge, T; Nobes, J; et al. (2018-04) -
RE-ARMing the Immune Response to Bladder Cancer with Radiotherapy.
Wilkins, A; Hall, E; Lewis, R; Gribble, H; Melcher, A; et al. (ELSEVIER SCIENCE LONDON, 2022-07-01)